US 12,083,224 B2
Lipid particles for nucleic acid delivery
Padmanabh Chivukula, San Diego, CA (US); Priya Karmali, San Diego, CA (US); Christine Esau, San Diego, CA (US); Jerel Vega, San Diego, CA (US); Yanjie Bao, San Diego, CA (US); Rajesh Mukthavaram, San Deigo, CA (US); and Samantha Murphy, Carlsbad, CA (US)
Assigned to Arcturus Therapeutics, Inc., San Diego, CA (US)
Appl. No. 17/042,848
Filed by Arcturus Therapeutics, Inc., San Diego, CA (US)
PCT Filed Apr. 1, 2019, PCT No. PCT/US2019/025246
§ 371(c)(1), (2) Date Sep. 28, 2020,
PCT Pub. No. WO2019/191780, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/651,020, filed on Mar. 30, 2018.
Prior Publication US 2023/0149310 A1, May 18, 2023
Int. Cl. A61K 31/7088 (2006.01); A61K 9/127 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 39/12 (2006.01)
CPC A61K 9/1272 (2013.01) [A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61K 39/12 (2013.01)] 17 Claims
 
1. A method of inducing an immune response in a subject comprising administering to the subject a pharmaceutical composition, the pharmaceutical composition comprising
a lipid-NA nanoparticle comprising lipids and a nucleic acid (NA), the lipid-NA particle encapsulating the nucleic acid;
wherein the lipids comprise a phospholipid, a cholesterol, a PEG-lipid, and a lipid of formula I

OG Complex Work Unit Chemistry
wherein
R1 and R2 are the same or different, each a linear or branched alkyl or alkenyl consisting of 3 to 31 carbons,
R3 is a linear or branched alkylene consisting of 1 to 6 carbons,
R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons;
L1 is a linear alkylene of 1 to 20 carbons or a linear alkenylene of 2 to 20 carbons,
L2 is a linear alkylene of 1 to 20 carbons, a linear alkenylene of 2 to 20 carbons, or L2 is a bond; and
wherein the nucleic acid encodes an immunogenic peptide and the nucleic acid has a nucleotide (nt) length of 200 to 25,000 nt.